All In Biotech

Drug Trial Radar · NCT07235995

Acetaminophen-Mannitol Injection and Postoperative Delirium

Effect of Analgesia With Acetaminophen-Mannitol Injection on Postoperative Delirium in Older Patients Undergoing Non-cardiac Surgery: Protocol for an Open-label Randomized Controlled Trial

Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 1,092 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,092

Planned (sponsor's estimate)

Start

Feb 2, 2026

Primary completion

Jan 31, 2027

Study completion Apr 30, 2027

Sponsor

Lead sponsor
Xiangya Hospital of Central South UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 19, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this multicenter randomized controlled study is to evaluate the effect of an intravenous acetaminophen-mannitol opioid-sparing analgesic strategy on the cumulative incidence of POD, compared with an intravenous sufentanil-based opioid analgesic strategy.

Conditions

  • Postoperative Delirium

Interventions

  • Acetaminophen groupDrug

    The pain in this group is controlled using acetaminophen-mannitol (Paracetamol and Maninitol Injection, Yichang Renfu Medicine Co., Ltd., China), 500 mg, intravenous bolus, every 6 hours for the first 48 hours after randomization. The severity of pain is assessed using NRS/CPOT every 15 minutes during the first hour after randomization with study drug infusion and then once every 12 hours needed.The NRS will be used for awake patients, and the CPOT will be used for mechanically ventilated patients.

  • Sufentanil groupDrug

    The pain in this group is controlled using sufentanil (Yichang Renfu Medicine Co., Ltd., China) intravenous infusion with a rate of 0.05 μg/kg/h. The severity of pain is assessed using NRS/CPOT every 15 minutes during the first hour after randomization with study drug infusion and then once every 12 hours needed.The NRS will be used for awake patients, and the CPOT will be used for mechanically ventilated patients.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of deliriumTime frame: postoperative 1- 5 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Xiangya hospital

    Changsha, Hunan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.